Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA due to it's high cost and limited access. NBC News' Yamiche Alcindor spoke ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...

The discovery could help explain why some cancer patients respond well to certain treatments, while others are not so lucky.

The Man Who Wants to Live Forever introduced many viewers to the Minicircle company, and here's what the organization ...

Sangamo plans to explore all options to commercialize the Hemophilia A asset.

New Delhi, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.26 billion by 2033 at a CAGR ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...

Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV, vectors. While AAV-based treatments have ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle ...